Antiscalants/Scale Inhibitors Industry The global antiscalants/scale inhibitors market is projected to reach $5.5 billion by 2032, growing ...

Antiscalants/Scale Inhibitors Industry The global antiscalants/scale inhibitors market is projected to reach $5.5 billion by 2032, growing at a CAGR of 4.7% from 2023 to 2032. WILMINGTON, DE, UNITED S ...

Researchers have found in a new study that PCSK9 inhibitors can be safely and effectively used for lipid-lowering therapy in ...

Until now, the early phase of drug discovery for the development of new therapeutics has been both cost- and time-intensive.

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer care across a wide range of tumor types and disease ...

and formation damage and inhibitor retention core flood tests. This process facilitates a reduced number of scale inhibitors to proceed onto further compelling areas of research, such as the ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Background Current international guidelines suggest andexanet alfa (AA) for the management of factor Xa inhibitor-associated intracranial haemorrhage (ICH ... and good functional outcome (modified ...

Clinical question What are the benefits and harms of medications for adults with type 2 diabetes at varied risks of cardiovascular and kidney related complications? Context Emerging clinical trials of ...

A multidisciplinary medical team has conducted one of few large-scale and costly studies in Bulgaria involving ...